Key result
VEGFR-2 inhibition proportionally drives hypertension risk, predominantly when unbound plasma levels exceed ~0.1-fold of IC50.
Why the study?
Several anti-angiogenic cancer drugs inhibiting VEGFR signalling cause hypertension, and quantifying the relationship between VEGFR-2 inhibition and blood pressure elevation is needed for TKI development.
Does the degree of VEGFR-2 inhibition by tyrosine kinase inhibitors predict the risk of drug-induced blood pressure elevation?
Does the degree of VEGFR-2 inhibition by tyrosine kinase inhibitors predict the risk of drug-induced blood pressure elevation?
Answers are grounded in this paper and cite their sources.
The risk of TKI-induced hypertension is proportional to VEGFR-2 inhibition, and maintaining a >10-fold margin between VEGFR-2 IC50 and unbound plasma concentration minimizes this risk.
Background and Purpose Several anti‐angiogenic cancer drugs that inhibit VEGF receptor (VEGFR) signalling for efficacy are associated with a 15–60% incidence of hypertension. Tyrosine kinase inhibitors (TKIs) that have off‐target activity at VEGFR‐2 may also cause blood pressure elevation as an undesirable side effect. Therefore, the ability to translate VEGFR‐2 off‐target potency into blood pressure elevation would be useful in development of novel TKIs. Here, we have sought to quantify the relationship between VEGFR‐2 inhibition and blood pressure elevation for a range of kinase inhibitors. Experimental Approach Porcine aortic endothelial cells overexpressing VEGFR‐2 (PAE) were used to determine IC50 for VEGFR‐2 phosphorylation. These IC50 values were compared with published reports of exposure attained during clinical use and the corresponding incidence of all‐grade hypertension. Unbound average plasma concentration (Cav,u) was selected to be the most appropriate pharmacokinetic parameter. The pharmacokinetic‐pharmacodynamic (PKPD) relationship for blood pressure elevation was investigated for selected kinase inhibitors, using data derived either from clinical papers or from rat telemetry experiments. Key Results All‐grade hypertension was predominantly observed when the Cav,u was >0.1‐fold of the VEGFR‐2 (PAE) IC50. Furthermore, based on the PKPD analysis, an exposure‐dependent blood pressure elevation >1 mmHg was observed only when the Cav,u was >0.1‐fold of the VEGFR‐2 (PAE) IC50. Conclusions and Implications Taken together, these data show that the risk of blood pressure elevation is proportional to the amount of VEGFR‐2 inhibition, and a margin of >10‐fold between VEGFR‐2 IC50 and Cav,u appears to confer a minimal risk of hypertension.
No takes yet. Share an insight, caveat, or question.
Collins et al. (2017) studied Hypertension associated with kinase inhibitors. VEGFR-2 inhibition by kinase inhibitors was evaluated on Blood pressure elevation and all-grade hypertension. The risk of blood pressure elevation is proportional to VEGFR-2 inhibition, with hypertension predominantly observed when unbound average plasma concentration is >0.1-fold of the VEGFR-2 IC50.
Synapse has enriched 10 related papers. Consider them for comparative context: